163 related articles for article (PubMed ID: 27077926)
21. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.
Sanfilippo R; Dileo P; Blay JY; Constantinidou A; Le Cesne A; Benson C; Vizzini L; Contu M; Baldi GG; Dei Tos AP; Casali PG
Anticancer Drugs; 2015 Jul; 26(6):678-81. PubMed ID: 25763543
[TBL] [Abstract][Full Text] [Related]
22. Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
Laroche A; Chaire V; Le Loarer F; Algéo MP; Rey C; Tran K; Lucchesi C; Italiano A
J Hematol Oncol; 2017 Apr; 10(1):84. PubMed ID: 28399901
[TBL] [Abstract][Full Text] [Related]
23. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
24. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
[TBL] [Abstract][Full Text] [Related]
25. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
26. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
27. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.
Colmegna B; Uboldi S; Frapolli R; Licandro SA; Panini N; Galmarini CM; Badri N; Spanswick VJ; Bingham JP; Kiakos K; Erba E; Hartley JA; D'Incalci M
Br J Cancer; 2015 Dec; 113(12):1687-93. PubMed ID: 26633559
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA
Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246
[TBL] [Abstract][Full Text] [Related]
30. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.
Li WW; Takahashi N; Jhanwar S; Cordon-Cardo C; Elisseyeff Y; Jimeno J; Faircloth G; Bertino JR
Clin Cancer Res; 2001 Sep; 7(9):2908-11. PubMed ID: 11555609
[TBL] [Abstract][Full Text] [Related]
31. Unique features of trabectedin mechanism of action.
Larsen AK; Galmarini CM; D'Incalci M
Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
[TBL] [Abstract][Full Text] [Related]
32. Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line.
Peraldo Neia C; Cavalloni G; Chiorino G; Ostano P; Aglietta M; Leone F
Oncotarget; 2016 Dec; 7(52):86766-86780. PubMed ID: 27902465
[TBL] [Abstract][Full Text] [Related]
33. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.
Tavecchio M; Natoli C; Ubezio P; Erba E; D'Incalci M
Cell Prolif; 2007 Dec; 40(6):885-904. PubMed ID: 18021177
[TBL] [Abstract][Full Text] [Related]
34. In vitro radiosensitisation by trabectedin in human cancer cell lines.
Romero J; Zapata I; Córdoba S; Jimeno JM; López-Martín JA; Tercero JC; De La Torre A; Vargas JA; Molerón R; Sánchez-Prieto R
Eur J Cancer; 2008 Aug; 44(12):1726-33. PubMed ID: 18501589
[TBL] [Abstract][Full Text] [Related]
35. Role of homologous recombination in trabectedin-induced DNA damage.
Tavecchio M; Simone M; Erba E; Chiolo I; Liberi G; Foiani M; D'Incalci M; Damia G
Eur J Cancer; 2008 Mar; 44(4):609-18. PubMed ID: 18243687
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
Dossi R; Frapolli R; Di Giandomenico S; Paracchini L; Bozzi F; Brich S; Castiglioni V; Borsotti P; Belotti D; Uboldi S; Sanfilippo R; Erba E; Giavazzi R; Marchini S; Pilotti S; D'Incalci M; Taraboletti G
Int J Cancer; 2015 Feb; 136(3):721-9. PubMed ID: 24917554
[TBL] [Abstract][Full Text] [Related]
37. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
38. Trabectedin has promising antineoplastic activity in high-grade meningioma.
Preusser M; Spiegl-Kreinecker S; Lötsch D; Wöhrer A; Schmook M; Dieckmann K; Saringer W; Marosi C; Berger W
Cancer; 2012 Oct; 118(20):5038-49. PubMed ID: 22392434
[TBL] [Abstract][Full Text] [Related]
39. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.
David-Cordonnier MH; Gajate C; Olmea O; Laine W; de la Iglesia-Vicente J; Perez C; Cuevas C; Otero G; Manzanares I; Bailly C; Mollinedo F
Chem Biol; 2005 Nov; 12(11):1201-10. PubMed ID: 16298299
[TBL] [Abstract][Full Text] [Related]
40. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
Le Cesne A
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]